Safety and efficacy of dolutegravir + optimised background antiretroviral combinations in antiretroviral-experienced patients with HIV-2 infection within the French Named Patient Program

Trial Profile

Safety and efficacy of dolutegravir + optimised background antiretroviral combinations in antiretroviral-experienced patients with HIV-2 infection within the French Named Patient Program

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2015

At a glance

  • Drugs Dolutegravir (Primary) ; Abacavir; Darunavir; Didanosine; Emtricitabine; Foscarnet; Lamivudine; Lopinavir; Maraviroc; Ritonavir; Saquinavir; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-2 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top